MOTS-c
Worth trying, BioHarmony verdict
BioHarmony score 6.0 out of 10
MOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway. Human evidence remains observational: Zhou 2024 pooled seven biomarker studies, but no published human RCT has tested exogenous MOTS-c for clinical outcomes.
Read full reportWhat is MOTS-c?
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded inside the mitochondrial 12S rRNA region. The core finding from Lee 2015 is that MOTS-c can regulate insulin sensitivity and metabolic homeostasis by inhibiting the folate and purine biosynthesis pathway, raising AICAR, and activating AMPK, the same energy-sensing pathway stimulated by exercise and caloric stress.
From the BioHarmony report, reviewed Sep 8, 2026.
Saved on this device only.
How it is thought to work
Inhibits ATIC in the folate and purine biosynthesis pathway, increases AICAR, activates AMPK, and can translocate to the nucleus during metabolic stress per Kim 2018.
Safety watch-outs
- Injection-site infection
- Hypoglycemia symptoms
- Severe fatigue or muscle weakness
Full risk profile in the BioHarmony report.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
No approved-label or study protocol is recorded for MOTS-c yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (6)
Attributed viewpoints, separate from primary research.
- Stem Cells, Peptides, and the Real Reason You're Getting Old Dr. Adeel Khan,
- Peptides to Promote Cellular Health Dr. Suzanne Ferree,
- Why Longevity Protocols Fail: Peptides, Stacks & the Science of Precision Alex Kikel,
- My Top Peptide Stack for Mental Clarity & Muscle Repair Alex Kikel,
- MOTS-c Vs. SS-31 | Which Mitochondria Peptide Is Right For You? Hunter Williams,
- MOTS-C vs SLU-PP-332: Which Fat Loss Mimetic Wins? Jay Campbell,
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
FDA identifies immunogenicity and impurity concerns for compounded MOTS-c and says it has not identified human exposure data or enough information to determine harm.
Primary sources
- Certain bulk drug substances for use in compounding that may present significant safety risks U.S. Food and Drug Administration,
Related peptides for weight & metabolic
- 6.1TirzepatideTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
- 6.0TesamorelinTesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for…
- 5.9Semaglutide (GLP-1 Agonist)Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds…
- 5.8CagrilintideCagrilintide (AM833) is a long-acting amylin receptor analogue that drove about 11.8 percent weight loss as monotherapy at 68 weeks in REDEFINE 1 per Garvey 2025, with…
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.